Article
Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Oncogene - 1 Apr 2020
Wang Yin, Liu Yan, Bailey Christopher, Zhang Huixia, He Miao, Sun Duxin, Zhang Peng, Parkin Brian, Baer Maria R, Zheng Pan, Malek Sami N, Liu Yang
Abstract excerpt
TP53 mutation in acute myeloid leukemia (AML) is associated with poor prognosis. Since no targeted therapy is available to restore p53 function, it is of great interest to test whether other pathways activated by TP53 mutations can be therapeutically targeted. Here, we showed HIF-1α target genes are enriched in TP53-mutated versus TP53-wild-type AML. To determine the role of this activation, we tested efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.